Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to the downside, just as we often do when the market reacts to the upside.
Here’s a look at three fallen angels trading near their 52-week lows that could be worth buying.
This year has certainly been the year of going green, with anything solar or electric-vehicle-based shooting to the moon. The latest in a serious of rocket stocks is China’s Kandi Technologies (NASDAQ: KNDI ) , which has basically doubled in just the past two weeks following the Chinese government’s approval of the company’s first all-electric sedan. Given the success of Tesla Motors (NASDAQ: TSLA ) in the U.S., many are suspecting that Kandi will be a surefire winner with Geely Automotive in its corner as a partner. As for me, I’m not as convinced.
Hot Tech Companies To Own For 2014: Sonus Networks Inc.(SONS)
Sonus Networks, Inc. provides voice and multimedia infrastructure solutions. The company offers session border control (SBC), voice over Internet protocol (VoIP), and access and VoIP media gateway solutions that allow the delivery of voice and multimedia sessions over IP networks. Its products include GSX9000 Open Services Switch that enables voice traffic to be transported over packet networks; GSX4000 Open Services Switch; NBS9000 Network Border Switch that permits service providers to transform their time division multiplexing networks to IP; PSX Policy & Routing Server, which translates business policies into actual call control, routing, and service selection decisions; NBS5200 Network Border Switch that provides SBC functionality; and ASX Call Feature Server that provides local area calling and regulatory features for residential and enterprise markets. The company also offers Network Analytics Suite of performance management products, including NetScore network perf ormance analysis tool, NetAssure voice quality monitoring tool, and NetEng network audit and visualization engine that are used for the collection, monitoring, reporting, and notification of performance metrics. In addition, it provides professional consulting and services to support its IP communication solutions; and program management, network deployment design, softswitch and subscriber database design, network verification and audit, custom application and adaptor development, OSS and API integration, migration and upgrade, and managed services. The company serves long-distance and local exchange carriers, Internet service providers, wireless operators, cable operators, financial institutions, retailers, state and local governments, and multinational corporations. It sells its products primarily through a direct sales force in the United States, Europe, the Asia-Pacific, and the Middle East. Sonus Networks, Inc. was founded in 1997 and is headquartered in Westford, Mas s achusetts.
- [By Roberto Pedone]
One networking player that’s starting to move within range of triggering a big breakout trade is Sonus Networks (SONS), which provides networked solutions for communications service providers and enterprises in the U.S., Europe, the Middle East, Africa, and the Asia Pacific. This stock has been red hot so far in 2013, with shares up 104%.
If you take a look at the chart for Sonus Networks, you’ll notice that this stock has been trending sideways for the past month, with shares moving between $3.25 on the downside and $3.72 on the upside. Shares of SONS have been finding support over the last month each time the stock has pulled back to its 50-day moving average. This stock is now starting to trend a bit higher and move within range of triggering a breakout trade above the upper-end of its sideways consolidating chart pattern.
Traders should now look for long-biased trades in SONS if it manages to break out above some near-term overhead resistance at $3.56 to $3.59 a share and then once it takes out its 52-week high at $3.72 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.50 million shares. If that breakout hits soon, then SONS will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that breakout are $5 to $5.50 a share.
Traders can look to buy SONS off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.33 to $3.25 a share, or right below more support at $3.10 a share. One could also buy SONS off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Tech Companies To Own For 2014: Dyadic International Inc (DYAI)
Dyadic International, Inc. (Dyadic), incorporated in September 2002, is a holding company. The Company is a global biotechnology company. The Company has operations at the United States and the Netherlands. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of enzymes and proteins for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies, the sale of its enzymes and conducting research and development (R&D) activities for third parties. The Company operates in two segments: the United States operations and The Netherlands operations. The United States segment includes a subsidiary in Poland.
The United States operating segment is a developer, manufacturer and distributor of enzyme products, proteins, peptides and other bio-molecules derived from genes and a collaborative licensor of enabling technologies for the development and manufacturing of biological products and use in R&D. The Netherlands operating segment is also a researcher and developer of enzyme products, proteins, peptides and other bio-molecules derived from genes and, to date, has mainly invested in R&D activities.